Background: Due to the rapid development of next-generation sequencing (NGS) and precision medicine, molecularly driven targeted therapy, for different tumor types, plays an important role in cancer patients with drug targets. mucosal melanoma (MM) is aggressive disease with a poor prognosis. there are few studies focusing on its target drug. Methods: We enrolled female patients with melanoma (n = 24) from 2019.** to 2021.** cancer database with a gynecological tumor site. Subsequently, we chose to use WES sequencing to predict possible targets in patients. Results: In all mutations of the 24 melanoma patients, we screen the mutations about the drug targets. And the result shown that BRAF somatic mutations were identified in 6 of the 24 samples (25%), which are the highest frequency drug targets. V600E substitutions accounted for 3 (50%) of these mutations as target drug. Other activating mutations at NRAS codons 61 and 12/13 were lower frequent (Q61*, n = 3; G13D, n = 1; G12A, n = 1). TP53 and TOP2B were mutated in 4(16%) tumors were found as drug targets. Conclusions: This study aimed to analyze the target drug interaction of MM in China and lay a support for targeted therapy. NGS in MM is feasible with potential impact in half of our cohort. Earlier testing and improved trial drug from drug bank database access is necessary to increase the like hood that MM patients may benefit from drug target guided therapy.